Table 5.

Effect of biologic therapy on disability

ILAR subtype	SJIA	OJIA	RF− PJIA	RF+ PJIA	ERA	JPsA	Subtype unknown	Total	P
Number of patients	11	38	19	36	24	26	71	225
Baseline HAQa	1.69 (1.25–2.13)	2 (1.63–2.3)	1.81 (1.25–2.25)	2.06 (1.56–2.44)	1.44 (0.63–1.75)	2.0 (1.38–2.63)	2.06 (1.5–2.5)	2 (1.5–2.4)	0.08
6-month HAQb	1.75 (0.88–1.88)	1.63 (0.75–2.13)	1.5 (1.0–2.13)	1.75 (1–2.5)	1.13 (0.38–1.38)	1.75 (1.5–2.0)	1.69 (0.75–2.13)	1.75 (0.88–1.88)	0.18
Change in HAQ at 6 months	0.56 (0.25–0.81)	0.38 (0–0.63)	0.56 (0.25–0.75)	0.13 (–0.13–0.5)	0.31 (–0.06–0.63)	0.38 (0.13–0.63)	0.5 (0.13–0.88)	0.38 (0–0.63)	0.36
Percentage MCID HAQ at 6 months	75	62	88	42	63	67	65	63	0.33
12-month HAQc	0.63 (0.25–1.5)	1.56 (0.56–2.13)	1.63 (1.25–1.88)	2.06 (0.81–2.5)	1.25 (0–1.38)	1.63 (1.13–1.81)	1.5 (0.75–2.13)	1.5 (0.75–2.13)	0.07
Change in HAQ at 12 months	0.44 (0–0.94)	0.38 (0–0.63)	0.38 (0.38–0.63)	0.13 (0–0.38)	0.31 (0.13–0.5)	0.63 (0.25–0.75)	0.5 (0.13–0.75)	0.38 (0.13–0.75)	0.39
Percentage MCID HAQ at 12 months	50	64	83	43	63	79	73	67	0.38

All values median (IQR) or n (%). SJIA: systemic onset JIA; OJIA: oligoarticular JIA; RF− PJIA: RF-negative polyarticular JIA; RF+ PJIA: RF-positive polyarticular JIA; PJIA: psoriatic JIA; UnJIA: unclassifiable JIA. ^aNumber of patients with HAQ available at baseline: 197/225 (88%). ^bNumber of patients with HAQ available at 6 months: 137/225 (61%). ^cNumber of patients with HAQ available at 12 months: 126/225 (56%).